Magenta Therapeutics, Inc. (NASDAQ:MGTA) has a beta value of 2.85 and has seen 879,198 shares traded in the last trading session. The company, currently valued at $312.72 Million, closed the last trade at $7.92 per share which meant it lost -$0.3 on the day or -4.69% during that session. The MGTA stock price is -104.42% off its 52-week high price of $16.19 and 27.27% above the 52-week low of $5.76. If we look at the company’s 10-day average daily trading volume, we find that it stood at 541.99 Million shares traded. The 3-month trading volume is 218.64 Million shares.
Magenta Therapeutics, Inc. (NASDAQ:MGTA) trade information
Despite being -4.69% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jun 23 when the MGTA stock price touched $10.46- or saw a rise of 24.28%. Year-to-date, Magenta Therapeutics, Inc. shares have moved -47.76%, while the 5-day performance has seen it change -18.27%. Over the past 30 days, the shares of Magenta Therapeutics, Inc. (NASDAQ:MGTA) have changed -17.41%. Short interest in the company has seen 1.02 Million shares shorted with days to cover at 0.
Wall Street analysts have a consensus price target for the stock at $18, which means that the shares’ value could jump 127.27% from current levels. The projected low price target is $15 while the price target rests at a high of $22. In that case, then, we find that the current price level is +177.78% off the targeted high while a plunge would see the stock lose 89.39% from current levels.
Magenta Therapeutics, Inc. (MGTA) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +0% over the past 5 years. Earnings growth for 2020 is a modest +33.8% while over the next 5 years, the company’s earnings are expected to increase by 0%.
Magenta Therapeutics, Inc. (NASDAQ:MGTA)’s Major holders
Insiders own 16.23% of the company shares, while shares held by institutions stand at 75.2% with a share float percentage of 89.76%. Investors are also buoyed by the number of investors in a company, with Magenta Therapeutics, Inc. having a total of 114 institutions that hold shares in the company. The top two institutional holders are TRV GP IV, LLC with over 8.01 Million shares worth more than $50.29 Million. As of March 30, 2020, TRV GP IV, LLC held 20.28% of shares outstanding.
The other major institutional holder is Gilder, Gagnon, Howe & Co., with the holding of over 4.06 Million shares as of March 30, 2020. The firm’s total holdings are worth over $25.5 Million and represent 10.28% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Mutual Fund Ser Tr-Eventide Gilead Fund and Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund. As of December 30, 2019, the former fund manager holds about 5.15% shares in the company for having 2034248 shares of worth $30.84 Million while later fund manager owns 1.36 Million shares of worth $20.61 Million as of December 30, 2019, which makes it owner of about 3.44% of company’s outstanding stock.